Last reviewed · How we verify
Best oral medication
This drug works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys.
This drug works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys. Used for Type 2 diabetes, Heart failure.
At a glance
| Generic name | Best oral medication |
|---|---|
| Sponsor | University Hospital Tuebingen |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, the drug reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine. This results in decreased blood glucose levels. The drug also has effects on the cardiovascular system, including reduced blood pressure and decreased risk of hospitalization for heart failure.
Approved indications
- Type 2 diabetes
- Heart failure
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
- Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections (PHASE2)
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections. (PHASE3)
- MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence (NA)
- Phase II Study of Regorafenib as Maintenance Therapy (PHASE2)
- Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease (PHASE3)
- Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (PHASE1)
- Effect of Clinical Pharmacist Consultation on Pain Management (NA)
- CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Best oral medication CI brief — competitive landscape report
- Best oral medication updates RSS · CI watch RSS
- University Hospital Tuebingen portfolio CI